Arizona United Rheumatology Alliance
2016 Annual Meeting
June 3 – 5, 2016
The Enchantment Resort
Sedona, Arizona

REGISTRATION BROCHURE

Obtain detailed meeting information and/or register quickly and easily online at tinyurl.com/AURA2016
In particular, there is a ‘preclinical’ phase during which there are circulating abnormalities of disease-specific autoantibodies in absence of treatment.

Rheumatoid arthritis (RA) is now known to develop in phases. In this phase, the possibility of ever attaining treatment-free remissions in the future may point to new directions for therapeutic advances, as we consider the inflammatory effector functions that cause tissue injury. Understanding and treatment of rheumatic disease with pharmaceuticals necessitates a mutual understanding of the pathobiology of the eye disease, the impact of the immunomodulatory therapy on the inflammation, the limitations of the available agents to truncate inflammation and the anticipated outcomes with and without appropriate treatment.

The involvement of the Rheumatologist in treating Ocular Inflammatory disease with pharmaceuticals necessitates a mutual understanding of the pathobiology of the eye disease, the impact of the immunomodulatory therapy on the inflammation, the limitations of the available agents to truncate inflammation and the anticipated outcomes with and without appropriate treatment.

The microbiome is the collection of bacteria, archea and viruses that populate our every surface. Our immune system evolved under the influence of commensal bacteria that affect every aspect of our nutritional status, immune defenses and capacity to maintain homeostasis. New technological tools have enabled the characterization of variations in the microbiome communities that populate us using Next Generation Sequencing, which side-steps the biases and limitations of culture-dependent approaches. We are beginning to recognize how imbalances in our microbiota lead to distortions in otherwise protective commensal-mediated pathways, resulting in initiation or worsening of our rheumatic autoimmune diseases. These autoantibodies can be used to identify individuals who are at high risk for future RA. Based on this, there are several prevention trials for RA underway that are using blood testing for RA-related autoantibodies to identify individuals who are at high-risk for future RA, and then treat them with a pharmacologic agent to try and prevent future disease. If these trials are successful, in the near future we may be fundamentally changing how we treat RA. As such, health-care providers who care for patients with rheumatic disease should understand the preclinical phase of RA, and basics of disease prediction and possible preventive strategies.

The microbiome is the collection of bacteria, archea and viruses that populate our every surface. Our immune system evolved under the influence of commensal bacteria that affect every aspect of our nutritional status, immune defenses and capacity to maintain homeostasis. New technological tools have enabled the characterization of variations in the microbiome communities that populate us using Next Generation Sequencing, which side-steps the biases and limitations of culture-dependent approaches. We are beginning to recognize how imbalances in our microbiota lead to distortions in otherwise protective commensal-mediated pathways, resulting in initiation or worsening of our rheumatic autoimmune diseases. These autoantibodies can be used to identify individuals who are at high risk for future RA. Based on this, there are several prevention trials for RA underway that are using blood testing for RA-related autoantibodies to identify individuals who are at high-risk for future RA, and then treat them with a pharmacologic agent to try and prevent future disease. If these trials are successful, in the near future we may be fundamentally changing how we treat RA. As such, health-care providers who care for patients with rheumatic disease should understand the preclinical phase of RA, and basics of disease prediction and possible preventive strategies.

The microbiome is the collection of bacteria, archea and viruses that populate our every surface. Our immune system evolved under the influence of commensal bacteria that affect every aspect of our nutritional status, immune defenses and capacity to maintain homeostasis. New technological tools have enabled the characterization of variations in the microbiome communities that populate us using Next Generation Sequencing, which side-steps the biases and limitations of culture-dependent approaches. We are beginning to recognize how imbalances in our microbiota lead to distortions in otherwise protective commensal-mediated pathways, resulting in initiation or worsening of our rheumatic autoimmune diseases. These autoantibodies can be used to identify individuals who are at high risk for future RA. Based on this, there are several prevention trials for RA underway that are using blood testing for RA-related autoantibodies to identify individuals who are at high-risk for future RA, and then treat them with a pharmacologic agent to try and prevent future disease. If these trials are successful, in the near future we may be fundamentally changing how we treat RA. As such, health-care providers who care for patients with rheumatic disease should understand the preclinical phase of RA, and basics of disease prediction and possible preventive strategies.

The microbiome is the collection of bacteria, archea and viruses that populate our every surface. Our immune system evolved under the influence of commensal bacteria that affect every aspect of our nutritional status, immune defenses and capacity to maintain homeostasis. New technological tools have enabled the characterization of variations in the microbiome communities that populate us using Next Generation Sequencing, which side-steps the biases and limitations of culture-dependent approaches. We are beginning to recognize how imbalances in our microbiota lead to distortions in otherwise protective commensal-mediated pathways, resulting in initiation or worsening of our rheumatic autoimmune diseases. These autoantibodies can be used to identify individuals who are at high risk for future RA. Based on this, there are several prevention trials for RA underway that are using blood testing for RA-related autoantibodies to identify individuals who are at high-risk for future RA, and then treat them with a pharmacologic agent to try and prevent future disease. If these trials are successful, in the near future we may be fundamentally changing how we treat RA. As such, health-care providers who care for patients with rheumatic disease should understand the preclinical phase of RA, and basics of disease prediction and possible preventive strategies.
including implications for RA diagnosis, predictors of prognosis, disease pathways, novel therapeutic approaches and future prospects for a role for genetic testing in the clinical setting.

**EDUCATIONAL OBJECTIVES**

At the conclusion of the AURA 2016 Annual Meeting, attendees should be able to:

1. Explain the epidemiology of knee, hip and hand osteoarthritis.
2. Describe current nonpharmacologic and pharmacologic interventions for pain and to alter the progression osteoarthritis.
3. Describe the optimal use of methotrexate.
4. Explain the most recent data that compares conventional combination therapy to methotrexate plus TNF inhibitors both in early rheumatoid arthritis and in patients who have had suboptimal responses to methotrexate.
5. Review evidence that in many autoimmune diseases breaches, immunologic tolerance leads to self-perpetuating pathogenic pathways of inflammatory tissue damage.
6. Explain how lessons from studies of memory B cells in rheumatoid arthritis may suggest metrics for better outcomes in the future.
7. Describe the current state of knowledge of the natural history of RA, with a focus on the ‘preclinical’ period of development.
8. Identify how biomarkers can be used to predict the future onset of RA.
9. Recognize ocular involvement in a few common Uveitic Syndromes.
10. Distinguish appropriate Immunomodulatory therapy for common Uveitic conditions.
11. Identify challenging pharmaceutical situations with newer immunomodulatory therapies.
12. Review basic principles and functional roles of our intestinal microbiomes.
13. Explain the state-of-the-art for microbiome research in inflammatory arthritis and SLE.
14. Identify which biologic pathways have been implicated in RA risk and severity.
15. Explain the potential for genetic discoveries to identify novel therapeutic targets for RA.

**SAPS CME ACCREDITATION STATEMENT:**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Southern Alliance for Physician Specialties and Arizona United Rheumatology Alliance. The Southern Alliance for Physician Specialties CME is accredited by the Medical Association of Georgia to provide continuing medical education for physicians.

The Southern Alliance for Physician Specialties CME designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Hotel Information**

Enchantment Resort
525 Boynton Canyon Road
Sedona, Arizona 86336
Main: (928) 282-2900
Fax: (928) 282-9249
Website: www.enchantmentresort.com

Enchantment Resort is fully booked and no longer has rooms available. Below is information for alternate hotel choices.

**ALTERNATE HOTELS**

*Please contact these hotels directly to make reservations.*

**Hyatt Pinon Pointe**
1 N AZ-89-ALT
Sedona, AZ 86336
(928) 204-8820
hyattpinonpointe.hyatt.com

**Sedona Rouge Hotel & Spa**
2250 W State Route 89a
Sedona, AZ 86336
(928) 203-4111
sedonarouge.com

**L’Auberge de Sedona**
301 Lauberge Lane
Sedona, AZ 86336
(855) 905-5745
lauerge.com

**Travel & Transportation**

**Airport Information**
The Phoenix Sky Harbor Airport is approximately 126.59 miles from Enchantment Resort or two hours and 10 minutes by car. The Sedona Airport used for charter and private flights is approximately nine miles from Enchantment Resort and 19 minutes by car.

**Taxi Cab Services**
Please follow the airport signs to locate the taxi stands.

**Rental Car Information**
Avis® Rent-A-Car is the official rental car company for the AURA meeting. For reservations, please call (800) 331-1600, and use the code “J901055” to receive the discounted rates.

**Parking**
Parking is included in the daily resort fee of $22 per room, per night, plus taxes.

**Registration Information**

**Registration Includes:**
- Entrance to scientific sessions
- Breakfasts
- One ticket to the Welcome Reception

**Special Needs**
For accommodations on the basis of disability or special dietary needs, please call (847) 517-7225.

**Questions**
Contact the AURA Executive Office by:
Phone: (847) 517-7225
Fax: (847) 517-7229
Email: aura@wjweiser.com
Please select the category that best describes your status:

- Rheumatologist
- Non Physician Provider
- Other Medical Professional
- Fellow
- Researcher
- Resident
- Industry Employee
- Other

How did you learn about this meeting?

- Calendar/Monthly Listing
- Website
- Email
- Word of Mouth/Colleague
- Registration Brochure Mailer

INDUSTRY EMPLOYEES ONLY

Industry Employee OR Industry Medical Science Liaison whose company is already supporting AURA

☐ $175

Industry Employee OR Industry Medical Science Liaison whose company is NOT already supporting AURA

☐ $1,250

Your submission will need to be approved prior to confirmation of your registration. Approval may be based on current Industry support. To find out if your company is currently supporting AURA, please contact Brittany Kallman in the Registration Department at (847) 264-5963 or by email at brittany@wjweiser.com.

Please print clearly

First Name: __________________________ Last Name: __________________________

Degree(s): __________________________ Badge First Name: __________________________

Address: ____________________________________________________________ ☐ Home ☐ Office

City: __________________________ State: __________________________ Zip: __________________________

Phone: __________________________ Fax: __________________________ Email: __________________________

MEETING REGISTRATION

Registration Categories

- Physician
- Non-Physician Provider
- Student (Graduation Year: __________)
- Resident (Graduation Year: __________)
- Fellow (Graduation Year: __________)
- Allied Health Professionals

Complimentary

Total Registration Fee: __________________________

Will you be attending the Annual Dinner on Saturday, June 4, 2016?

☐ Yes ☐ No

Please indicate how many additional guests you will be bringing to the Annual Dinner: __________________________

PAYMENT INFORMATION:

AURA requires payment for registration fees by check or credit card.

- Check (payable to WJ Weiser & Associates Meetings)
- Visa
- MasterCard
- American Express

Please note: If paying by credit card, the name WJ Weiser & Associates (the management company of AURA) will appear on your statement.

Credit Card #: __________________________ Expiration Date: __________________________ CVV#: __________________________

Name on Credit Card: __________________________

Billing Address: __________________________

Signature: __________________________

The issuer of the card identified on this item is authorized to pay the amount shown as TOTAL upon proper presentation. I promise to pay such TOTAL (together with any other charges due thereon) subject to and in accordance with the agreement governing the use of such card.

Questions

Contact the AURA Executive Office by:

Phone: (847) 517-7225
Fax: (847) 517-7229
Email: aura@wjweiser.com

PHONE REGISTRATIONS CANNOT BE ACCEPTED. Acceptable registration methods include:

- By Fax: (847) 517-7229
- By Mail: AURA, Two Woodfield Lake, 1100 E. Woodfield Road, Suite 350, Schaumburg, IL 60173-5116
- Online: tinyurl.com/AURA2016
## Program Schedule

### 2016 Arizona United Rheumatology Alliance Annual Meeting

June 3 - 5, 2016

All sessions will be in the **Anasazi I Room** unless otherwise noted.

Speakers and times are subject to change.

#### FRIDAY, JUNE 03, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 p.m. - 8:30 p.m.</td>
<td>Registration/Information Desk Open</td>
<td>Anasazi Foyer</td>
</tr>
<tr>
<td>6:00 p.m. - 8:30 p.m.</td>
<td>Welcome Reception</td>
<td>Anasazi II &amp; III</td>
</tr>
</tbody>
</table>

#### SATURDAY, JUNE 04, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 a.m. - 1:30 p.m.</td>
<td>Registration/Information Desk Open</td>
<td>Anasazi Foyer</td>
</tr>
<tr>
<td>6:30 a.m. - 1:30 p.m.</td>
<td>Exhibit Hall Open</td>
<td>Anasazi II &amp; III</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m. - 8:00 a.m.</td>
<td>Industry Satellite Symposium Breakfast</td>
<td>Agave Ballroom</td>
</tr>
<tr>
<td>6:00 p.m. - 7:30 p.m.</td>
<td>Annual Dinner</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45 a.m. - 7:55 a.m.</td>
<td>Welcome</td>
<td></td>
</tr>
<tr>
<td>8:00 a.m. - 8:45 a.m.</td>
<td>Osteoarthritis in Rheumatoid Arthritis: New Notions and Therapeutic Interventions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Nancy E. Lane, MD UC Davis Hillsborough, CA</td>
<td></td>
</tr>
<tr>
<td>9:00 a.m. - 9:45 a.m.</td>
<td>Nonbiologic DMARDs in Rheumatoid Arthritis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: James R. O’Dell, MD University of Nebraska Medical Center Omaha, NE</td>
<td></td>
</tr>
<tr>
<td>9:45 a.m. - 10:15 a.m.</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:15 a.m. - 11:00 a.m.</td>
<td>Can We Wipe the Immune System Clean In Autoimmune Disease?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Gregg J. Silverman, MD NYU School of Medicine New York City, NY</td>
<td></td>
</tr>
<tr>
<td>11:00 a.m. - 12:00 p.m.</td>
<td>Preclinical Rheumatoid Arthritis: Pathogenesis, Prediction, Prevention</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Kevin D. Deane, MD University of Colorado School of Medicine Aurora, CO</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 p.m. - 1:00 p.m.</td>
<td>Industry Satellite Symposium Luncheon</td>
<td>Agave Ballroom</td>
</tr>
</tbody>
</table>

#### SUNDAY, JUNE 05, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m. - 8:00 a.m.</td>
<td>Industry Satellite Symposium Breakfast</td>
<td>Agave Ballroom</td>
</tr>
<tr>
<td>8:00 a.m. - 8:45 a.m.</td>
<td>Inflammatory Eye Disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Mandi Conway, MD FACS Arizona Retinal Specialists Sun City West, AZ</td>
<td></td>
</tr>
<tr>
<td>9:00 a.m. - 9:45 a.m.</td>
<td>Human Microbiome and SLE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Gregg J. Silverman, MD NYU School of Medicine New York City, NY</td>
<td></td>
</tr>
<tr>
<td>9:45 a.m. - 10:15 a.m.</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:15 a.m. - 11:00 a.m.</td>
<td>Genetic Epidemiology of Rheumatoid Arthritis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Lindsey A. Criswell, MD MPH UCSF-Box 0500 San Fransisco, CA</td>
<td></td>
</tr>
<tr>
<td>11:15 a.m. - 12:00 p.m.</td>
<td>The Science of Biologics and Biosimilars</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Alan L. Epstein, MD Pennsylvania Rheumatology Associates, P.C. Philadelphia, PA</td>
<td></td>
</tr>
</tbody>
</table>

*Outside CME Accreditation*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 p.m. - 1:00 p.m.</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

### Disclaimer Statement

Statements, opinions and results of studies contained in the program and abstracts are those of the presenters/authors and do not reflect the policy or position of AURA nor does AURA provide any warranty as to their accuracy or reliability.

## General Meeting Information

### Registration/Information Desk Hours

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, June 3, 2016</td>
<td>5:00 p.m. – 8:30 p.m.</td>
<td>Anasazi Foyer</td>
</tr>
<tr>
<td>Saturday, June 4, 2016</td>
<td>6:30 a.m. – 1:30 p.m.</td>
<td>Anasazi II &amp; III</td>
</tr>
<tr>
<td>Sunday, June 5, 2016</td>
<td>7:00 a.m. – 11:45 p.m.</td>
<td></td>
</tr>
</tbody>
</table>

### Exhibit Hall Hours

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, June 3, 2016</td>
<td>6:00 p.m. – 8:30 p.m.</td>
<td>Anasazi II &amp; III</td>
</tr>
<tr>
<td>Saturday, June 4, 2016</td>
<td>6:30 a.m. – 1:30 p.m.</td>
<td></td>
</tr>
<tr>
<td>Sunday, June 5, 2016</td>
<td>7:00 a.m. – 10:30 a.m.</td>
<td></td>
</tr>
</tbody>
</table>